Knowledge Base

Resources & Guides

Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.

Showing articles tagged: #triumph trials Clear filter

Educational Content

View all →
Showing 3 of 3 articles
No articles found matching your search. Try a different term or view all articles.

Is Retatrutide FDA Approved? Status, Trials & Timeline (2026)

Retatrutide is not FDA-approved. It's currently in Phase 3 clinical trials (TRIUMPH program) with expected approval in 2027. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.

When Will Retatrutide Be FDA Approved? Timeline, Trials & Projections (2026)

A current read on the retatrutide FDA timeline. The molecule is still investigational, Lilly plans to submit a Biologics License Application (BLA) in Q1 2027, and the most defensible approval window is late 2027 to 2028. Here is what TRIUMPH Phase 3 has reported, what happens next, and how the timeline compares with tirzepatide.

How to Get Retatrutide: Clinical Trials and Expanded Access Are the Only Lawful Routes

Retatrutide isn't FDA-approved yet. Lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). This guide covers how to join a trial, who qualifies for expanded access, why compounding pharmacies cannot lawfully supply retatrutide, and what research peptide vendors actually sell, plus what you need to know about safety, legality, and costs.